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Health economists and outcomes researchers have watched
the term ‘big data’ increase in prominence over the last
several years. However, to date, the use of big data in
medicine has not been concretely illustrated across a
variety of health economics and outcomes research
(HEOR). At the same time, many of the same observers
agree that fundamental questions remain unanswered and
include (1) ‘‘What does the term ‘big data’ mean?’’ and (2)
‘‘What does the availability of big data mean for individ-
uals who produce and use findings from HEOR?’’ This
editorial tackles the first question and leaves contributors to
this issue of PharmacoEconomics to discuss the promises,
possibilities and potential pitfalls of using big data in
HEOR.
Big data refers to large amounts of information that
require new technologies for capture, storage or analysis,
due in part to the amount of information, the speed at
which it is generated, and its content. Two approaches have
been used in formally defining big data [1]: the 3V defi-
nition [2, 3] and the 4V definition [4]. The 3V definition
includes volume, variety and velocity [2, 3]. According to
Berman [2], for data to be properly characterized as big
data, we must be able to talk about ‘‘the size, complexity,
and restlessness’’ of the data. The 4V definition adds
‘value’ to the list [4]. In their description of big data, Gantz
and Reinsel [4] note that big data ‘‘is not only about the
original content stored or being consumed but also about
the information around its consumption.’’ Thus, big data
involves technology and system architecture, not only
content. Smartphones are often used to illustrate the com-
plexity of big data. In addition to providing information
that is easily captured as flat files or simple-format records,
they can also provide more complex data like geographic
location, motion and direction information [2].
In this section, the 4V definition is used to describe big
data in terms of its volume, variety, velocity and value. The
large amounts of information from health records, social
media, server logs, Web clickstream, machine/sensor and
geolocation data illustrate the volume of big data [2, 5].
The variety of big data represents the different potential
sources (e.g. administrative data, electronic health records,
sensors, smartphones, social networks) and formats (e.g.
video, audio, text or image) [1, 2]. The velocity of big data
relates to the speed at which data transfers occur as well as
to the rapidly changing nature of the data due to the
sources, formats and categories of the contributing data [1,
2]. Value, ‘‘the most important aspect of big data’’ [1],
relates to the untapped potential for drawing important,
unique and transformative insights from big data. This
fourth characteristic of big data has important implications
for clinical research and population health research [6].
This special issue focuses on the application to population
health research and particularly HEOR.
The full-length articles in this special issue draw on one
or more of the components of the 4V definition and con-
tribute to our understanding of the role of big data in
HEOR. Contributions were sought that addressed impor-
tant aspects of HEOR, including data sources, measure-
ment, regression modelling and simulation. Additionally,
the goal was to include a geographically diverse set of
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applications to highlight perspectives across institutional,
government and health system settings. The articles illus-
trate innovative, linked data sources and discuss practical
considerations for their development, reliability and use in
HEOR (e.g. Lorgelly et al. [7] and Thorn et al. [8]). The
articles discuss the practical challenges and opportunities
with regards to measurement of healthcare cost and uti-
lization using large, complex datasets (e.g. Canavan et al.
[9], Payakachat et al. [10], Asaria et al. [11]). The articles
utilize analytic methods and tools that are particularly
suited for developing evidence from large-volume datasets.
These articles illustrate the use of classification and
regression trees for analysing prescribing patterns [12],
clustering algorithms for cost prediction [13] and data
visualization tools for examining prescription drug fill
patterns [14]. Last but not least, the full-length articles in
this special issue describe innovative opportunities for
linking dynamic simulation modelling (DSM) with elec-
tronic health records [15] and integrating DSM with big
data for evidence generation [16].
Together, these articles offer a much-needed snapshot of
current data sources, analytic methods, opportunities and
challenges. The hope is that future work will offer addi-
tional insights and lessons learned to increase our knowl-
edge of the role of big data in HEOR. This knowledge base
is important given that observational data, whether used for
regression or simulation modelling, are critical to evidence
generation in HEOR. We will need to be sure that big data
provide more value and not more noise. As we consider the
availability of more complex data, we cannot forget what
we already know about the importance of study design or
the appropriate interpretation of study findings. We cannot
assume that more data necessarily means more informa-
tion. Indeed, as the volume of data increases, it will be
important to pay continued (or more) attention to estab-
lished concerns regarding measurement, bias, and fallacies
relevant to empirical analysis and interpretation. We
should keep in mind points offered in William Crown’s
commentary [17] on model specification and big data,
including his point that more data is not an automatic
source of bias reduction. It is also important to note the
strengths, weaknesses, opportunities and threats discussed
in Brendan Collins’ commentary [18].
With regards to the role of big data in HEOR, we will
need thoughtful data linkages, model specifications, and
interpretation to leverage the potential of big data. We will
also need richer measures, including environmental mea-
sures (e.g. physical and social environmental measures of
place and space), economic measures (e.g. income mea-
sured at an individual or small-area level), clinical mea-
sures (‘health record’-type detail with ‘experimental
study’-type accuracy) and utilization measures (including
accurate, validated measures where needed). In addition,
we should have a clear sense of what may be missing (e.g.
preferences, opportunity costs, direct nonmedical and
intangible costs) and who may be missing (e.g. the unin-
sured, the homeless, the medically underserved, the insured
individual who does not utilize health services) from the
data to identify creative ways to leverage the breadth and
depth of big data.
The papers in this special issue provide practical,
provocative discussions regarding the use of large, com-
plex data in HEOR. We hope that these papers spur con-
tinued discussions because the availability of big data is
neither a silver bullet nor a temporary distraction. Devel-
opments in information technology will support its con-
tinued relevance into the foreseeable future. The
opportunities for linking clinical, cost and contextual data,
as well as the challenges that arise in this undertaking are
welcome developments. They challenge us to continue
efforts to improve the conduct and translation of HEOR for
real-world impact.
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